Earnings ·
CRISPR Therapeutics AG reported financial results for the quarter ended June 30, 2026
CRSPCRISPR Therapeutics AG
CRISPR Therapeutics AG reported financial results for the quarter ended June 30, 2026. The company generated $76 million in CASGEVY revenue, reflecting 151% year-over-year growth. Net loss narrowed to $91.2 million from $208.5 million in the prior year period, driven by reduced R&D and G&A expenses alongside increased collaboration revenue. Cash reserves rose to $2,364.4 million following a $585.4 million convertible senior notes issuance in March 2026. The FDA approved CASGEVY for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia. Additionally, the company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using CRISPR/Cas9 technology.